SCM
CRBP icon

Segantii Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Segantii Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,880
Closed -$465K – 102
2017
Q1 		$465K Buy
1,880
+1,640
+683% +$403K 0.08% 84
2016
Q4 		$62K Buy
+240
New +$55K 0.02% 72

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Segantii Capital Management's CRBP Position: Q2 2017 in Review

Segantii Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2017, closing a stake of 1,880 shares — an estimated $465K sold.

Segantii Capital Management first reported a position in CRBP in Q4 2016 and held it in 2 quarters. The position peaked at $465K in Q1 2017. 69 funds tracked by Wall St. Rank hold CRBP as of Q2 2017.

  • Segantii Capital Management reported no remaining Corbus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 1,880 Corbus Pharmaceuticals shares in Q2 2017, an estimated $465K.
  • Segantii Capital Management first reported a position in Corbus Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Segantii Capital Management's Corbus Pharmaceuticals position peaked at $465K in Q1 2017.
  • 69 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.